Volume 23, Number 1—January 2017
CME ACTIVITY - Research
Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
Table 2
Medical history of AIG-IV recipients and nonrecipients, Scotland, UK, 2009–2010*
Variable | AIG-IV nonrecipient | AIG-IV recipient | p value |
---|---|---|---|
Presentation and clinical history | |||
Days from exposure to symptom onset, median (IQR) | 1 (0.0–4.0), n = 18 | 2 (1.0–4.5), n = 12 | 0.19 |
Days from symptom onset to hospitalization, median (IQR) | 2 (1.0–3.0), n = 25 | 2.0 (1.0–5.0), n = 14 | 0.55 |
Age, y, mean ± SE | 34.2 ± 1.5, n = 28 | 37.5 ± 1.6, n = 15 | 0.18 |
Male sex | 60.7 (17/28) | 73.3 (11/15) | 0.41 |
Smoker | 94.4 (17/18) | 81.8 (9/11) | 0.54 |
Alcohol user | 33.3 (5/15) | 58.3 (7/12) | 0.19 |
Hepatitis C infection |
60 (9/15) |
77.8 (7/9) |
0.66 |
Drug injection route and site | |||
Intravenous | 50 (14/18) | 40 (6/15) | 0.53 |
Intramuscular | 21.4 (6/28) | 46.7 (7/15) | 0.16 |
Arm | 39.3 (11/28) | 26.7 (4/15) | 0.41 |
Groin | 25 (7/28) | 26.7 (4/15) | 1.00 |
Buttock | 7.1 (2/28) | 26.7 (4/15) | 0.16 |
Leg |
10.7(3/28) |
6.7 (1/15) |
1.00 |
Presenting complaints | |||
Local† | 67.9 (19/28) | 53.3 (8/15) | 0.54 |
General‡ | 17.9 (5/28) | 20.0 (3/15) | |
Both% | 14.3 (4/28) | 26.7 (4/15) |
*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate number of patients for whom data were available. AIG-IV, anthrax immune globulin intravenous; IQR, interquartile range.
†Skin lesion, limb swelling, or limb pain.
‡Fever, diaphoresis, confusion, seizures, lethargy, or malaise.
1These authors contributed equally to this article.